Molecular modeling study of DOT1L for the discovery of new potent inhibitors, drug for acute leukemia
- Swati Kamal
- Rahul Anand
- Sunita Sharma
Dot1L; inhibitor; mixed lineage leukemia; protein lysine methyltransferase; protein structure-based design
— The aim of the paper is to provide the current treatment for acute leukemia as the treatment options are limited and less effective. Genetic and small molecules inhibitors studies have demonstrated that the histone methyltranferase DOT1L is required for the development and maintenance of Acute leukemia in model system. Here in this paper we tried to describe the characterization of EPZ-5676, a potent and selective amino nucleoside inhibitor of DOT1L histone methyltransferase activity. The inhibitor of small molecules or shRNA by the inhibition of DOT1L activity to prevent proliferation of various rearranged leukemia cells in vitro, making DOT1L as captivating therapeutic target for acute leukemia. Many drugs are currently in use to treat this disease but have low efficiency hence here we focused on various natural components which lowers the toxic effect of the target receptor.
Swati Kamal, Rahul Anand, Sunita Sharma. "Molecular modeling study of DOT1L for the discovery of new potent inhibitors, drug for acute leukemia".INTERNATIONAL JOURNAL OF ENGINEERING DEVELOPMENT AND RESEARCH ISSN:2321-9939, Vol.4, Issue 3, pp.904-910, URL :https://rjwave.org/ijedr/papers/IJEDR1603146.pdf
Volume 4 Issue 3
Pages. 904-910
